Immunotherapy that blocks microglial Fcγ receptors prevents dopaminergic neuron loss in Parkinson’s disease, revealing a potential new strategy.

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

The two companies plan to expand their collaboration around Sinorda Biomedicine’s potential pipeline, including multiple integrated projects.

Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.

Cardiff Oncology saw its shares nosedive following the departure of its CEO and CFO, plus questions about some Phase II data for its candidate onvansertib in first-line RAS-mutated metastatic ...

Prior seasonal influenza virus immunity did not impair antibody responses or protection conferred by the intranasal H5N1 vaccine.

Sidewinder achieves highly accurate assembly of long DNA sequences from scratch, offering a new leap forward for programmable biology ...

The study's findings suggest that health outcomes reflect a complex interaction between genes, lifestyle, and viral history ...

NanoMosaic's technology is designed to support upstream and downstream process development, quality control, and release testing.

Disrupted hippocampal replay in an Alzheimer’s mouse model reveals how memory consolidation breaks down, offering clues for early diagnosis.

A new mouse study found that unrepaired DNA-protein crosslinks activate inflammatory signaling pathways that trigger early aging disorders.

Engineered BiTE molecule draws T cells to eliminate FAP+ modulated smooth muscle cells, reducing plaque burden across mouse atherosclerosis models.